B. Riley Securities Maintains Buy on Microbot Medical, Lowers Price Target to $3

Benzinga · 3d ago
B. Riley Securities analyst Anderson Schock maintains Microbot Medical (NASDAQ:MBOT) with a Buy and lowers the price target from $4 to $3.